NASH Treatment

View All

rezdiffra-journey-in-nash-treatment
Empowering Change: REZDIFFRA’s Trailblazing Journey in NASH Treatment

Liver disease emerges as a burgeoning global health concern, presenting a myriad of formidable challenges. From viral hepatitis to alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), liver cirrhosis, and hepatocellular carcinoma (HCC), these conditions collectively afflict millions, exacting a toll o...

Find More

rezdiffra-for-nash-treatment
Madrigal’s Rezdiffra Breakthrough Transforms NASH Treatment, Leading the Way for Next-Gen Therapies

The prolonged wait for an effective remedy for non-alcoholic steatohepatitis (NASH) has concluded with the FDA’s approval of the inaugural drug for this fatty liver condition. Madrigal Pharmaceuticals’ resmetirom, soon available as Rezdiffra, has achieved the milestone of becoming the primary therapy for NASH to re...

Find More

novel-drug-classes-for-nash-treatment
Game-Changers in Non-Alcoholic Steatohepatitis (NASH) Treatment: Insights into Novel Drug Classes

Non-alcoholic steatohepatitis (NASH) has emerged as a global health concern, affecting millions of individuals worldwide. NASH is a progressive liver disease characterized by inflammation and liver cell damage, often resulting from the accumulation of fat in the liver. According to DelveInsight’s evaluation in 2022...

Find More

pharma-news
Gene-edited T cells for diabetes treatment; Pliant raised $144 million; Accent, AstraZeneca aim RNA modifiers in cancer deal; NodThera Raises $55M;

Gene-edited T cells for diabetes treatment The Scientists at the Seattle Children's Research Institute and the Benaroya Research Institute have got a promising finding that will turn off the destructive autoimmune response in Type 1 diabetes. This comprises editing the genes of patients' T cells. The team pre...

Find More